Format

Send to

Choose Destination
Transfusion. 2015 Jul;55(7):1710-20. doi: 10.1111/trf.13100. Epub 2015 Apr 9.

Comparative effectiveness of plasma prepared with amotosalen-UVA pathogen inactivation and conventional plasma for support of liver transplantation.

Author information

1
Pôle des Pathologies Digestives-Hépatiques-Transplantations, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
2
EFS-Alsace, Strasbourg, France.
3
Cerus Corporation, Concord, California.
4
Association ARMESA, Strasbourg, France.

Abstract

BACKGROUND:

Liver transplant may require large-volume plasma transfusion with increased risk of transfusion-transmitted infection (TTI). Pathogen inactivation of plasma with amotosalen-UVA offers the potential to mitigate TTI risk.

STUDY DESIGN AND METHODS:

A retrospective cohort design was used to compare the therapeutic efficacy and key safety outcomes for liver transplants supported with quarantine plasma (Q-FFP [reference]) or amotosalen-UVA plasma (IBS plasma [test]). The outcomes evaluated were volume of plasma, the numbers of red blood cell (RBC) components, and the total dose of platelets (PLTs) transfused during and 7 days after transplant. The safety outcomes were acute hepatic artery thrombosis (HAT) and mortality.

RESULTS:

Transplantation and transfusion records for 212 Q-FFP transplants and 215 IBS plasma transplants were reviewed. Not all transplants required plasma; 161 received Q-FFP and 174 received IBS plasma. Among the transplants that required plasma, there were significant differences in median values between cohorts for delay to transplantation (p=0.002), model end-stage liver disease score (p<0.001), pretransplant hematocrit (p=0.006), and graft cold perfusion time (p=0.033). The median volumes of plasma transfused were not different for test and reference (2.160 L vs. 1.969 L, p=0.292). Transplants in the test cohort required a mean of 3.7% more RBC components (p=0.767) and on average a 16.5% increase in total PLT dose (p=0.518). No significant differences were observed for the frequency of acute HAT or mortality.

CONCLUSION:

In this retrospective study, IBS plasma provided therapeutic support of liver transplant not different from Q-FFP.

PMID:
25857325
DOI:
10.1111/trf.13100
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center